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Abstract
Background: Streptococcus pneumoniae serotype 1 causes > 20% of invasive disease, among all age
groups combined, in The Gambia. In contrast, it is rarely detected in carriage studies. This study
compares the molecular epidemiology of S. pneumoniae serotype 1 causing invasive disease in The
Gambia between 1996 and 2005 to those carried in the nasopharynx between 2004 and 2006.
Results: A total of 127 invasive and 36 nasopharyngeal carriage serotype 1 isolates were recovered
from individuals of all age groups and were analyzed by serotyping, antibiotic susceptibility testing
and MLST. MLST analysis revealed 23 different sequence types (STs), 18 of which were novel. The
most prevalent clone among the 163 isolates was ST618 (70.5%), followed by ST3575 (7.4%),
ST2084 (2.5%) and ST612 (2.5%). A single ST (ST618), previously shown to belong to the ST217
hypervirulent clonal complex, was frequent among carriage (61.1%) and invasive (72.7%) serotype
1 isolates. ST618 causing both paediatric and adult disease peaked annually in the hot dry season
and caused outbreak in 1997 and 2002.
Conclusion: For over a decade, isolates of ST618 have been the dominant lineage among serotype
1 carriage and disease isolates circulating in the Gambia. This lineage shows similar epidemiological
features to those of the meningococcus in the African meningitis belt being able to cause outbreaks
of disease
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Background
Streptococcus pneumoniae consists of at least 91 different
serotypes, the majority of which rarely cause disease; two
serotypes (1 and 5) cause > 30% of invasive disease,
among all age groups combined, in The Gambia [1]. Sero-
type 1 has the potential to cause epidemics – it was
recently a cause of outbreaks of meningitis in Burkina
Faso and Northern Ghana [2,3]. It has also been associ-
ated with outbreaks in crowded or closed communities [4-
6]. In contrast, it is only rarely detected in carriage studies
[7]. The available, licensed pneumococcal conjugate vac-
cine (Prevenar®) contains seven of the 91 pneumococcal
serotypes and does not contain conjugates of serotypes 1
and 5 [8]. A trial of a 9-valent pneumococcal conjugate
vaccine in a rural setting in The Gambia showed protective
efficacy against radiological pneumonia (37%) and all
invasive pneumococcal disease (50%) and reduced all
cause hospitalisations and mortality by 15% and 16%
respectively [9]. Although the 9-valent vaccine contained
serotype 1 glycoprotein, pneumococci of this serotype
caused a small number of cases of invasive disease, with
no reduction in vaccinated children [9], A combined anal-
ysis of the efficacy of serotype 1 vaccines against invasive
pneumococcal disease in The Gambia and South Africa
showed no evidence of protection against this serotype
(27%, 95% CI-120, 76), although these were the only two
trials that have assessed this and the total numbers of
cases were small [10] Genotyping analysis showed that all
but one (ST3336) of the eight S. pneumoniae serotype 1
isolates responsible for cases of invasive disease in The
Gambian conjugate vaccine trial exhibited ST618 [11]. To
understand the invasive potential of S. pneumoniae sero-
type 1 ST618 lineage, we investigated the molecular epide-
miology and invasive capacity of S. pneumoniae serotype 1
isolates from rural and urban Gambia obtained during the
period 1996–2006, comparing isolates obtained from
asymptomatic nasopharyngeal carriers or cases of invasive
pneumococcal disease in all age groups.
Methods
Invasive and carriage isolates
The S. pneumoniae serotype 1 isolates used in this study
were collected from four of the five geographically diverse
regions including the Kombos (urban, rural, and peri-
urban), Western (urban), Central (rural) and the Upper
River (rural) Regions of The Gambia between 1996 and
2006 (Table 1). S. pneumoniae serotype 1 carriage isolates
were recovered from nasopharyngeal swab specimens of
healthy Gambians as previously described [7,12]. A diag-
nosis of invasive disease was based on isolation of the
pneumococcus from blood, cerebro-spinal fluid (CSF),
lung aspirate, or a combination of sites as previously
described [1,9]. Isolates were stored at -70°C in 15% glyc-
erol broth before further testing. When more than one iso-
late was obtained during a single episode of illness, for
example from blood and CSF, multiple isolates have been
included in the analysis only if they differed by MLST and/
or antibiotic susceptibility pattern. Only one child had
two episodes of illness. Details of how children were
enrolled, followed up and investigated have been
described previously [1,7,9,12,13]. Written consent was
obtained from the parents and the trial was approved by
the Joint Gambia Government and MRC Ethics Commit-
tee and Ethics Committees at the London School of
Hygiene & Tropical Medicine and the World Health
Organization.
Table 1: Provenance of S. pneumoniae isolates used in this study
Surveillance Method‡‡ Geographic Area‡‡ Year of study Age range studied Invasive, n (%) Carriage, n (%) Reference
Routine hospital 
surveillance†
Kombos, WR 1996–2003 1 day-78 years 93(73.2) - [1], this study
Treatment trial* URR & CRR 2004–2005 4–46 months - 7(19.4) This study
Hib vaccine trial** WR 1997–2002 < 6 years 26(20.5) - [9]
Pneumococcal vaccine 
trial*
URR & CRR 2000–2004 2–29 months 8(6.3) - [13]
Pneumococcal vaccine 
trial*
URR & CRR 2003–2005 12–23 months - 14(38.9) This study
Carriage study WR 2004–2006 0.5–70 years - 15(41.7) [7,12]
Total - - - 127 (100) 36 (100)
†Isolates were collected from patients who presented routinely to the MRC outpatient clinic in Fajara, The Kombos [1].
*Isolates were collected during prospective studies or trials of vaccines or pneumonia case management regimens with a standardized surveillance 
system for invasive pneumococcal disease. Subjects may have been randomised to receive the nine-valent pneumococcal vaccine (5 isolates were 
from 4 PCV-vaccinated children and 3 isolates were from 2 non-PCV-vaccinated children) [9].or high dose amoxicillin [20], unpublished].
**Subjects were investigated for invasive bacterial disease during the course of an Hib vaccine effectiveness study [13].
n, refers to the number of serotype 1 isolates
‡‡Kombos (urban, rural, and peri-urban), WR; Western Region (urban), CRR; Central River Region (rural) and URR; Upper River Region (rural).
Notes: There is one year overlap between invasive and carriage isolates
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S. pneumoniae isolation, serotyping and antimicrobial 
susceptibility
S. pneumoniae isolation, serotyping and antimicrobial sus-
ceptibility testing were performed as described previously
[1,7,9]. When more than one isolate was obtained during
a single episode of illness, for example from blood and
CSF, multiple isolates were included in the analysis only
if they differed by MLST and/or antibiotic susceptibility
pattern. The MRC microbiology laboratory submits to the
external quality assurance programme of the United King-
dom National External Quality Assessment Service [14].
Multi locus sequencing typing (MLST)
S. pneumoniae isolates were streaked on blood agar and
incubated at 37°C for 18 hours. A single colony from each
isolate was picked, restreaked and incubated at 37°C for
18 hours. Genomic DNA templates were prepared from a
loopful of bacteria as described in the manufacturer's
instructions (Qiagen Genomic DNA Kit, UK). MLST was
performed as described [15]. The seven genes targeted are
aroE, gdh, gki, recP, spi, xpt and ddl. Amplifications for all
genes were carried out with approximately 0.2 μg DNA
template, 250 μM (each) deoxynucleoside triphosphates,
2.5 mM MgCl2, 25 pmol of primers, and 1 U of Taq
polymerase (Qiagen) in a 25 μl reaction mixture. PCR
cycling conditions were a 10 min hold at 94°C, followed
by 34 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C
for 1 min, and a final extension at 72°C for 5 min. 2 μl of
reaction mixtures were separated by 1.0% agarose gel elec-
trophoresis and visualized with ethidium bromide stain-
ing and UV illumination with a gel documentation system
(Gel Doc 2000; Bio-Rad, UK).
PCR products were purified and DNA sequenced on both
strands in-house in our Core Sequencing Facility in Fajara,
The Gambia. Sequences were edited and complementary
sense and antisense fragments were aligned using the
Laser Gene DNA star 7.1 software. The sequences were
submitted to the MLST database website [16] and
assigned existing or novel allele type numbers and
sequence type numbers defined by the database. This
multi microorganism database defines a novel allele type
if it contains one or more nucleotide changes from exist-
ing allele sequences. Composite sequence types (STs) are
assigned based on the set of allele types derived from each
of the seven loci. STs were analyzed for relatedness using
the eBURST v3 program [17]. Cluster analysis of allelic
profiles was performed using a categorical coefficient and
a graphic method called a minimum spanning tree with
Bionumerics software (version 4.0; Applied Maths, Sint-
Martens-Latem, Belgium).
Estimation of the invasiveness of clones
An empirical odds ratio (OR) was calculated with 95% CI
using stata to compare the probability of invasive disease
following colonisation with varying clones. An OR > 1
indicates an increased probability to cause invasive dis-
ease.
Results
Clinical epidemiology
Invasive S. pneumoniae isolates were recovered from spec-
imens of blood (75%), lung aspirate (14%), CSF (7%),
knee aspirate (3%) and abdominal aspirate (1%). The
median age of the patients with invasive disease was 6.0
years (IQR 2.3–30 years). The number of pneumococcal
isolates obtained from patients with invasive disease var-
ied from year to year (fig 1a) with peaks in 1997 and
2002. Yearly fluctuations were due largely to changes in
the number of pneumococci of ST618 obtained. Pneumo-
coccal isolates were obtained most frequently at the end of
the hot dry season (May), this seasonal peak being
accounted for largely by an increase in isolation of pneu-
mococci of ST618 (fig 1b).
Numbers of laboratory-confirmed serotype 1 pneumococcal isolates obtained from patients with invasive disease by (a) year and (b) month in the study areas f The Gambia fr m 1996–2006Figur 1
Numbers of laboratory-confirmed serotype 1 pneu-
mococcal isolates obtained from patients with inva-
sive disease by (a) year and (b) month in the study 
areas of The Gambia from 1996–2006. Bars indicate the 
total number of serotype 1 pneumococcal isolates; squares 
those belonging to ST 618 and diamonds those belonging to 
non-ST618 clones.
Figure 1a 
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The median age of the individuals from whom the 36 car-
ried isolates were obtained was 7.85 years (IQR 0.5–71
years).
Antibiotic susceptibility among carried and invasive 
isolates
All invasive and carriage isolates were susceptible to chlo-
ramphenicol, penicillin and cefotaxime, whilst suscepti-
bility to cotrimoxazole was 57% and 66% for carriage and
invasive isolates respectively (p = 0.028). Susceptibility to
tetracycline was 50% and 79% for carriage and invasive
isolates respectively (p = 0.0003).
Clonal relationship among invasive and carriage isolates 
and OR for invasiveness
The genetic cluster of the study isolates by BOX-PCR
showed many instances in which the same ST produced
different BOX-PCR patterns indicating heterogeneity
within ST (data not shown).
MLST showed that there were 23 unique sequence types
(ST) in the collection (8 from carriage isolates only, 10
from invasive isolates only and 5 from both). Eighteen of
these STs (78.2%) were novel, i.e. not found in the S.
pneumoniae MLST database [16]. The most prevalent clone
among the 163 isolates was ST618 (70.5%), followed by
ST3575 (7.4%), ST2084 (2.5%) and ST612 (2.5%). ST
618 represented 22 of 36 (61.1%) carried isolates and 93
of 128 (72.7%) invasive isolates (Table 2).
A high prevalence of ST 618 was linked to the dramatic
increase in the isolation rate for serotype 1 pneumococci
in The Gambia in 1997 (figure 1). The odds ratio of ST
618 causing invasive disease relative to non-ST 618 clones
was 1.74 (95%CI, 0.80–3.78; P = 0.162. In addition, there
was no significant association between ST 618 and disease
outcome (death or discharge from hospital). The odds
ratio of ST 618 causing death relative to non-ST 618 was
0.67 (95% CI, 0.16–3.31; P = 0.504) (data not shown).
An eBURST analysis that included the STs from this study
and all serotype 1 isolates for which STs was available in
the MLST database was performed using the stringent 6/7
identical loci definition. eBURST groups these ST into one
major (ST217) and two minor (ST618 and 303) clonal
complexes (data not shown). The results of cluster analy-
sis of all the serotype 1 STs using the minimum spanning
tree is shown in figure 2. Five of the 23 STs found in The
Gambian isolates (ST217, ST612, ST618, ST1331 and
ST2084) have been previously described [16] and are
Table 2: Sequence type distribution (ST) of S. pneumoniae isolates used in this study
Allele profiles No of isolates Total no. of Isolates
ST aroE gdh gki recP spi xpt ddl Carriage Invasive
ST217 10 18 4 1 7 19 9 1 5 6
ST612 10 18 4 1 7 19 31 1 3 4
ST 618 13 8 4 1 7 19 14 22 93 115
ST1331 13 8 4 1 7 19 9 1 1 2
ST2084 13 8 4 2 7 19 14 2 2 4
ST3570 7 18 4 1 7 19 31 1 0 1
ST3571 7 13 101 4 36 1 74 1 0 1
ST3574 13 8 4 1 7 19 19 2 0 2
ST3572 7 2 4 4 7 17 19 1 0 1
ST3573 13 8 4 15 7 19 14 0 1 1
ST3574 13 8 4 1 7 19 19 0 1 1
ST3575 10 191 4 1 7 19 9 0 12 12
ST1336 13 8 4 1 7 19 161 0 1 1
ST3576 5 17 4 4 6 1 17 0 1 1
ST3577 10 8 4 1 7 19 14 0 1 1
ST3578 1 8 193 5 6 58 8 0 1 1
ST3579 13 8 4 5 7 250 14 0 2 2
ST3580 10 13 53 1 72 19 31 0 1 1
ST3581 13 8 4 115 7 19 14 0 2 2
ST3582 12 43 194 1 181 49 31 1 0 1
ST3407 23 189 4 12 43 4 74 1 0 1
ST3583 2 20 4 38 27 88 6 1 0 1
ST3329 7 13 4 8 6 20 18 1 0 1
Total 36 (100) 127 (100) 163
Novel alleles are underlined.
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indicative of lineage B isolates found predominantly in
Africa and Israel [18].
Discovery of new MLST alleles
We discovered six new alleles including one gdh (191),
two gki (193,194), one recP (115) one, spi (181), and one
xpt (250).
Discussion
The high prevalence of ST618 among serotype 1 isolates
from the Gambia in both invasive and carriage isolates
suggest that this clone has spread widely in the country.
The increase in serotype 1 disease seen in The Gambia in
1997 and to a lesser extent in 2002 was due primarily to
cases caused by pneumococci of ST618. Because surveil-
lance procedure varied during the course of the study,
apparent variations in incidence from year to year must be
treated with caution but the data presented in figure 1a
suggests that there was significant outbreak of ST618 inva-
sive pneumococcal disease in The Gambia in 1997. The
number of isolates varied substantially by month of year
and this seasonal pattern is unlikely to have been con-
founded by differences in sampling techniques from year
to year. The increase in isolates observed at the end of the
dry season was due largely to ST618; isolates of other non-
ST618 and non-serotype 1 pneumococci (data not
shown) showed little variation from month to month.
The end of the dry season is the time of the year when
meningococcal epidemics reach their peak in the African
meningitis belt [19]. This suggests that serotype 1 pneu-
mococci of ST618 share some characteristics with menin-
gococci that make them more adapted for spreading in the
face of environmental extremes. This finding is in agree-
ment with the results of other studies in Ghana and
Burkina Faso [2,3]. Recent outbreaks of meningitis in
Ghana, Burkina Faso and Niger were associated with sero-
types 1 ST618 and its clonal complex ST217 [2,3]. How-
ever, in The Gambia, ST618 was associated more with
Clustering of STs by use of the minimum spanning treeFigure 2
Clustering of STs by use of the minimum spanning tree. Each circle represents an ST. The area of each circle corre-
sponds to the number of isolates. Thick, short, solid lines connect single-locus variants and thin, longer, solid lines connect 
double-locus variants. Unshaded (white) portions represent Gambian STs and shaded (black) portion represents ST found in 
the rest of the world.
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bacteriemia and pneumonia than with meningitis. In our
study invasive serotype 1 isolates were obtained using pas-
sive (health-facility-based) surveillance methods and
some invasive serotype 1 isolates could have been missed.
We have recently started a large surveillance study of inva-
sive pneumococcal disease in The Gambia using standard-
ized techniques which may provide more information on
the relative virulence of different genotypes.
A possible limitation of our study is that invasive and car-
riage isolates were collected during different but overlap-
ping time periods (invasive isolates 1996–2004; carriage
isolates 2003–2006) although both sources of isolates
encompassed persons living in a wide geographical area,
in different regions of The Gambia. Invasive isolates were
collected during trials of vaccines or pneumonia case
management regimens that used standardized surveil-
lance for invasive pneumococcal disease among children
enrolled in the trials, and from patients of all ages who
presented routinely to the MRC hospital in Fajara. In addi-
tion, the laboratory methods employed for the isolation
of pneumococcal varied over the years. Nonetheless, any
potential effect of these differences in surveillance meth-
ods should have affected all STs and not just ST 618.
The number of serotype 1 carriage isolates studied was
small because this serotype is only rarely recovered during
carriage studies [7]. Despite this we have been able to
show convincingly that serotype 1 pneumococci of ST618
are more common in both carriage and invasive disease
than serotype 1 pneumococci of other STs. The factors that
determine the transition from carriage to invasive pneu-
mococcal disease are not well understood and it is not
known why pneumococci of serotype 1 show a predilec-
tion for causing invasive disease. A recently published
study based on a world-wide, diverse collection of 166
serotype 1 isolates was restricted to invasive isolates [18];
the authors could not therefore calculate the invasive
potential of these genotypes. In our study, the OR of
ST618 for causing invasive disease relative to non-ST618
serotype 1 isolates was not significant 1.74 (95%CI,
0.80–3.78; P = 0.162) and there was no association
between genotype (ST) and disease outcome. Interest-
ingly, an eBURST analysis has previously shown that
ST618 belongs to the ST217 clonal complex that caused
an outbreak of meningitis in Ghana. [2]. In addition to
ST618, the other STs found in this study included ST
3575, ST217 ST612, ST1331 and ST2084 (Table 2). ST
3575, a novel clone was only isolated from sporadic inva-
sive sources in the Kombos region in The Gambia between
1996–1999 with 20% case fatality (data not shown). All
these STs belong to the lineage B ST217 clonal complex
[18] but they were not significantly associated with ele-
vated odds of invasive disease in this study. Lineage B is
common in Africa and Israel, and distinct from lineage A
and C. Lineage A isolates and ST have been found exclu-
sively in Europe and North America and lineage C isolates
have come mainly from Chile [18].
We found greater susceptibility to cotrimoxazole and tet-
racycline antibiotics among invasive isolates than among
carriage serotype 1 isolates. It is encouraging that in The
Gambia, pneumococcal serotype 1 isolates are still sensi-
tive to chloramphenicol, which remains a first line treat-
ment for severe pneumonia, septicaemia and meningitis
locally (Steve Howie, personal communication) and is
more affordable than cefotaxime or ciprofloxacin.
The predominance of serotype 1 clones such as ST618,
that are not included in the current 7-valent conjugate vac-
cine, is of concern. Close surveillance of this clone is
needed to monitor any possible increase after the intro-
duction of vaccine. Changes over time after vaccination
will, however, need to be interpreted with caution since
we and others have shown substantial variation in inci-
dence from year to year [2], and an increase after the intro-
duction of vaccination may not necessarily indicate that
replacement infection has occurred.
Conclusion
For over a decade, isolates of ST618 have been the domi-
nant lineage among serotype 1 carriage and disease iso-
lates circulating in the Gambia. The existence of such an
epidemic clone with stability in time and over geographi-
cal distance is interesting. ST618 also shows similar epide-
miological features to those of the meningococcus in the
African meningitis belt being able to cause outbreaks of
disease.
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